

Disclosures

Personal Commercial (15)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Applied Clinical Intel	Consultant Fees/Honoraria	Modest (< \$5,000)	Stable Ischemic Heart Disease
Astra Zeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Cromos Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Acute Coronary Syndromes
Implicit Biosciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Janssen	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Kiniksa	Research/Research Grants	Significant (>= \$5,000)	Pericardial Disease
Kiniksa	Consultant Fees/Honoraria	Modest (< \$5,000)	Pericardial Disease
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Olatec	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
R-PHARM	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Serpin Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Swedish Orphan Biovitrum	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Swedish Orphan Biovitrum	Other - Supply of drug for research studies	None (\$0)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
National Institute of Health	Research/Research Grants ‡ RED-HART, D-HART2, VCU-ART3	Significant (>= \$5,000)	Acute Coronary Syndromes Heart Failure and Cardiomyopathies

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/14/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/14/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

On-Going Obligation Agreement | Signed on 2/27/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.